Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news!
re:wash trade, per my accountant, no big deal, even if you take a loss since the main issue is that the loss is disallowed--just an accounting issue. If you are out completely before year end their is no tax consequence.
SDS--I sold most of mine between 32.40 and 32.74. I like it over SH, which I also sold today but at a small loss due to poor initial entry.
I have been thinking along the same lines, but then hit a wall on deciding what to do to protect my family. It appears the market has support for now, but when the government makes a miscue, what do we
do?
Slowly reducing market exposure and parking it in cash. El-Erian has a recent article on SA that is worth thinking about. I tried to link it but SA is down at the moment.
He talks about two types of risk.
FDA approves “convalescent plasma” for COVID-19 treatment—on a case-by-case basis:
https://www.wsj.com/articles/fda-approves-plasma-treatment-for-coronavirus-under-certain-circumstances-11585090669
New 10 k out. For once, I do not mind the bonuses.
ITEM 9B. OTHER INFORMATION
On March 2, 2020, upon recommendation of the Compensation Committee of the Board of Directors, the Board of Directors approved annual performance bonuses pursuant to their employment contracts and objectives set by the Company to the following persons in the following amounts: Donald Pettigrew, President and Chief Executive Officer - $262,440; Karen Fisher, Chief Financial Officer - $94,725; and Manuel Marques, Chief Operating Agreement - $83,525.
Interesting AH trades, last at 10.50. Will it carry through?
Good day today. I've been dribbling a few shares out above $10.
My next license plate will be KRMD.
re SEAC--do you think they are hedging or making an educated guess that it is likely to spike over 5 before October?
Do you set limits on your shorts?
Wow. Flying pig? I've been long since $26 and added bigly when it dropped under 100 late last year. Data analytics is leading edge, and AYX is the leader. I expect it may retrace a bit, but this is a long term keeper.
Have you looked at their prior guidance and reported earnings?
They have a history of low-balling, and a 100% history of exceeding guidance.
And they are actually profitable...
This is their revenue growth history:
2016: 57 67
2017: 61 50 55 55
2018: 50 54 59 57
2019: 51 59 65 75
The 2016 numbers are not lining up, should be q3 and q4
The accounting for the quarter and year are almost complete. Expect a PR next week announcing the preliminary numbers and setting the date/time for earnings release and CC on the following week.
Do you work for the accounting firm?
It does not appear to have any recognition for this. But regardless, I suspect the company will not remain independent past this year.
Looks like a low volume take down before the next buying spree.
SEAC--I missed the specific $28 million reference but just past the 13 min mark the CFO stated the range to hit their low/high end targets was 22/32 million, so I estimate 27 million for the mid-point.
SEAC: what stands out from the transcripts is the cash position.
"The only financial metric that was disappointing in the quarter was our cash balance of $13.8 million at the quarter end.
The good news is that we believe our cash position is stabilized and the actions we are taking now to right size the cost structure of the company, combined with our strong sales momentum should set us up to be cash flow positive going forward."
Perhaps a financing in discussion is suppressing the price?
Later in the call they said they expected to be cash flow positive in q4, so the burn should slow a bit.
Low volume day--will they run it up into the close?
I was mistaken about option grants-it appears management was granted shares on 12-31. Perhaps end of year bonus? Unclear.
That is what I have been saying--the strength in share price and volume suggests to me there are underlying currents we are not privy to, as of yet.
Insider options granted today. See form 4's.
one hedge fund analysis:
Recent Portfolio ResultsKoru Medical (KRMD)—recently changed its ticker and company name from Repro-Med (REPR)KRMD was the biggest winner in the portfolio in Q3. It is a medical device company that has a razor/razorblade model that enables patients with primary immunodeficiency disease (“PIDD”) to self-administer plasma-derived treatments through subcutaneous infusion. There are roughly 270,000 people with PIDD in the U.S., but only ~70,000 (36%) are currently being treated. The primary reason for this large gap is that PIDD is difficult to diagnose, but awareness has been increasing. As a result, while the population with the disease is growing ~2% per year, the percentage of patients treated is growing closer to 10% per year. However, the story gets better for KRMD. Of the 70,000 patients currently being treated for PIDD, nearly 2/3 of those patients are being treated through intravenous therapy typically with one large dose per month in either a hospital or specialty clinic. This is suboptimal in several ways: it is inconvenient for the customer who has to go to the clinic and then receive a large dose through an IV, it is a high dose of a drug administered all at once (many patients feel sick afterwards and the effectiveness of the drug drops off significantly after a few weeks), and finally, it is veryexpensive for the healthcare industry since a dedicated facility and nurse are required.This is where KRMD’s solution enters the picture. KRMD’s subcutaneous infusion pump allows the patient to self-administer therapy at home, typically in smaller doses about once per week. The company currently has ~80% market share of the PIDD subcutaneous market---a market that is growing double digits and offers stable, recurring revenue. I know the drivers of this market fairly well given my previous work on PaySign Inc (PAYS). KRMD is in a different part of the plasma supply chainthan PAYS, but nonetheless benefits from double digit secular growth in patient count. I believe the company is undervalued based on their current PIDD and CIPD indicationsdue to 20%+ sustainable revenue growth, 70% gross margins, and significant operating leverage. Moreover, there is a chance that the current management team and board, which is impressive for a
micro-cap, can create value by extending the use of their pumps for other emerging subcutaneous drugs. If I am right, the stock could have multiples of upsidefrom current levels
With the volume and price change over the last several months, we must be missing something. I do not believe the uplisting alone would generate that response, so my best guess is that there are new or expanded uses for the Freedom system or sub Q drug delivery.
Could have been institutional money accumulating, with market on close execution.
SMSI relatively high volume on todays drop. Added a few.
KRMD I have started calling this kurmudgeon (curmudgeon) since it just keeps doing its thing, stubbornly moving in the direction it wants to go. Which fortunately for the long term holders is upwards.
Trading at 6.66 sure seems curmudgeonly too.
Research report for sale.
Interesting to see them first on this list:
High Flow Needle Set Market Report 2019 Along With Statistics Forecasts Till 2025 (RMS Medical Products, Medline Industries, Inc., MEDIWIDE and many more..)
The competition in the global High Flow Needle Set Market is analyzed, taking into consideration price, revenue, sales, and market share by company, market concentration rate, competitive situations and trends, expansion, merger and acquisition, and market shares of top 5 & 10 companies.
Top growing players in the High Flow Needle Set market –
RMS Medical Products
Medline Industries, Inc.
MEDIWIDE
Norfolk Medical
Braun Medical Inc.
GEORGE PHILIPS MEDICAL ENGINEERING Pvt. Ltd.
Thermo Fisher Scientific
Smiths Group plc.
IMD
Amdel
https://stewardnomist.com/2019/12/16/high-flow-needle-set-market-report-2019-along-with-statistics-forecasts-till-2025-rms-medical-products-medline-industries-inc-mediwide-and-many-more/
Wow, nice volume today. Lots of churning but the trend appears up.
INMD on sale, picked up a few.
I saw a 10,000 share offer at 5.90 and was wondering if that would slow down the buying, but those were snapped up quickly.
What to do. We need news to be made public. Trading at this volume tells me there is news--maybe after hours?
Wow, relentless buying. I am sure management would sell if the right offer came along. I am thankful to be along for the ride. What comes next?
OT: cholesterol story. I have been following the discussion here on statins and Vascepa with some interest since my cardiologist wants me on one. Last test was 270 with a high/low breakdown of 52/182 and trigs 176. No history of disease.
He agreed to let me try diet modification, so I went on a vegan diet loosely following Rip Esselstyn rescue diet for 10 days and got it down to 190 with a 44/113 breakdown and trigs little changed at 172. Probably beer and wine.
I remain unclear what part of the diet may have done the most good,
but results certainly give me impetus to keep on it.
Interested on cardiologist response, appt upcoming. He has everyone in his family on one regardless of risk or test results.
PCTI on track for 5X average volume. Someone likes it.
Exceeded my expectations! Gratz to all holders--sure made my day.
Why is the board under Canadian 3D category?
I have also seen positive news released just before earnings used to soften a disappointing earnings report. They could have released this info in conjunction with earnings, or after earnings to keep momentum rolling if earnings were good.
So a coin toss, imo.
Could you provide a link, I do not recall a filing, thanks.
I wonder who is buying, and why? There is a piece or two missing to this puzzle.
MKRS: hard to make sense of it:
ADEPT is a test set:
Adaptive Diagnostic Electronic Portable Testset is an indispensable tool for the maintenance, alignment, calibration, and error diagnosis of complex electronic systems.
ADSSS - They still receiving orders for ADSSS:
ADEPT Distance Support Sensor Suite (ADSSS) uses Smart Sensors, Model-Based Prognostics and Secure Fault-Tolerant Networking to implement Condition Based Maintenance for mission-critical complex distributed systems.
Mikros Systems Announces Delivery Order of up to $15 million for Advanced Maintenance Systems on Navy Littoral Combat Ship
Why is it rebounding?
I thought there was ETF buying/selling on these changes to indices.
Combined with the large short interest and insider buying, there might be a trigger. Forgot where I saw it, but CLF is one of Michael Burry's top current holding.
CLF being added to index. Possible index buying, or non-event?
https://finance.yahoo.com/news/mercury-systems-set-join-p-221500049.html